Uruguay and Brazil Deepen Medical Cannabis Cooperation

Uruguay hosted a technical delegation from Brazil’s National Health Surveillance Agency (ANVISA) on a visit aimed at strengthening bilateral cooperation in medical cannabis. The agenda included discussions on regulatory issues, tours of companies, and meetings with various stakeholders in the sector.

Uruguay strengthens its leadership in medical cannabis through regional cooperation and regulatory innovation

Brazil has established itself as the dominant player in the export of medicines and active pharmaceutical ingredients, with approximately 2.4 tons and over $450,000 exported to Uruguay in 2025. It also accounts for virtually all exported volume of CBD oils and isolates with THC concentrations <1%, confirming its role as a key destination for manufactured products.

These exports are carried out through two mechanisms regulated by ANVISA: the sale of medical cannabis products in pharmacies (RDC 1015/2026) and the compassionate use regime of direct sales to patients (RDC 660/2022). Therefore, having ANVISA’s highly experienced technicians in Uruguay proved to be of particular interest to technical and business teams, as well as to Uruguayan authorities.

The technical visit, coordinated by the Ministry of Public Health through the National Program for Access to Medicinal Cannabis, had an inter-institutional welcoming committee made up of the Ministry of Industry, Energy and Mining (MIEM), the Ministry of Foreign Affairs (MRREE), Uruguay XXI, the Intendency of Canelones, the Institute for Regulation and Control of Cannabis (IRCCA) and the Chamber of Medicinal Cannabis Companies (CECAM).

The visit encompassed a week of diverse activities, beginning on Monday, June 22nd, at the Pando Science and Technology Park. The following day, a working group meeting was held to exchange experiences and best practices in medicinal cannabis. Participants included the Minister of Public Health and the Undersecretary of the Ministry of Industry, Energy and Mining, Daniel Olesker, along with technical teams and representatives from various companies.

The agenda continued throughout the week with visits to companies and organizations in the sector, such as Fotmer, Molemix, GreenMed, Grüne Labs, and the CASMU Medicinal Cannabis Clinic, providing opportunities for technical exchange and sharing of best practices.

Uruguay has made substantial progress with the recent creation of the Uruguayan Health Surveillance Agency (AVISU), establishing a regulatory entity that will help ensure that medicines and health technologies available in the country meet the highest standards of quality, safety and efficacy.

The visit by ANVISA technicians strengthened cooperation and bilateral exchange between regulatory bodies and the industrial and business sector. It also highlighted the strength of companies in a sector that demonstrates its capacity for innovation and offers high-quality products.

Furthermore, it was an event highly valued by all stakeholders, due to its contribution to strengthening the national medicinal cannabis ecosystem.

__

(Featured image by QuaintPlanet via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in gub. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.